Table 2

Prevalence of anaemia at the time of ART initiation stratified by clinical and immunological-related characteristics of HIV-infected adults at Debre Markos Comprehensive Specialized Hospital from 1 January 2014 to 31 December 2018 (n=468)

CharacteristicsFrequency (%)Anaemia statusP value
Anaemic (%)Not anaemic (%)
Pre-ART duration
 <6 months332 (70.94)122 (36.75)210 (63.25)0.227
 ≥6 months136 (29.06)42 (30.88)94 (69.12)
Past OI
 Yes78 (16.67)34 (43.59)44 (56.41)0.083
 No390 (83.33)130 (33.33)260 (66.67)
Past CPT treatment
 Yes93 (19.87)32 (34.41)61 (65.59)0.886
 No375 (80.13)132 (35.02)243 (64.80)
Past INH prophylaxis
 Yes15 (3.21)3 (20.00)12 (80.00)0.215
 No453 (96.79)161 (35.54)292 (64.46)
Past TB treatment history
 Yes14 (2.99)8 (57.14)6 (42.86)0.078
 No454 (97.01)156 (34.36)298 (65.64)
Baseline WHO clinical staging
 I197 (42.09)43 (21.83)154 (78.17)<0.001
 II121 (25.85)35 (28.93)86 (71.07)
 III121 (25.85)63 (52.07)58 (47.93)
 IV29 (6.20)23 (79.31)6 (20.69)
Baseline CD4 count (cells/μL)
 <10089 (19.02)62 (69.66)27 (30.34)<0.001
 100–19974 (15.81)41 (55.41)33 (44.59)
 200–349124 (26.50)34 (27.42)90 (72.58)
 ≥350181 (38.68)27 (14.92)154 (85.08)
Baseline BMI
 <18.5134 (28.63)78 (58.21)56 (41.79)<0.001
 18.5–24.9286 (61.11)76 (26.57)210 (73.43)
 >24.948 (10.26)10 (20.83)38 (79.17)
Baseline functional status
 Working370 (79.06)93 (25.14)277 (74.86)<0.001
 Ambulatory90 (19.23)65 (72.22)25 (27.78)
 Bedridden8 (1.71)6 (75.00)2 (25.00)
  • ART, antiretroviral therapy; BMI, body mass index; CPT, cotrimoxazole preventive therapy; INH, isoniazid; OI, opportunistic infection; TB, tuberculosis.